Survey of actual conditions of erythema marginatum as a prodromal symptom in Japanese patients with hereditary angioedema

• Published in: The World Allergy Organization journal 2021-02, Vol.14 (2), p.100511-100511, Article 100511
• Main Authors: Ohsawa, Isao, Fukunaga, Atsushi, Imamura, Shinya, Iwamoto, Kazumasa, Tanaka, Akio, Hide, Michihiro, Honda, Daisuke, Yamashita, Kouhei, Fujiwara, Chisako, Ishikawa, Osamu, Yamaguchi, Takeo, Maehara, Junichi, Hirose, Tomoya, Ieko, Masahiro, Umekita, Kunihiko, Nakamura, Yuya, Gotoh, Hiromichi
• Format: Article
• Language: English
• Subjects: Allergies; Angioedema; Bradykinin; C1-inhibitor; Edema; Erythema; Erythema marginatum; Females; Hereditary angioedema; Icatibant; Mutation; Patients; Physicians; Prodromal symptom; White people
• ISSN: 1939-4551; 1939-4551
• DOI: 10.1016/j.waojou.2021.100511

Hereditary angioedema (HAE) is a rare but life-threatening condition. HAE types I and II (HAE-1/2) result from C1-inhibitor (C1–INH) deficiency. However, recent genetic analysis has established a new type of HAE with normal C1–INH (HAEnC1-INH). The mutations of factor XII, plasminogen, angiopoietin 1, and kininogen 1 genes may be the cause of HAEnC1-INH. Nevertheless, other causative molecules (HAE-unknown) may be involved. The Japanese therapeutic environment for HAE has been improving owing to the self-subcutaneous injection of icatibant, which was approved for the treatment of acute attack and enables early therapy. Erythema marginatum (EM) is a visible prodromal symptom which occasionally occurs prior to an angioedema attack; hence, recognizing the risk of an acute attack is important for early treatment. However, the detailed characteristics of EM remain unclear. In this study, we first investigated the clinical manifestations of EM in Japanese patients with HAE. A 20-point survey was developed and distributed to 40 physicians to gather clinical data on EM from patients with HAE. Data on 68 patients with HAE (58 patients with HAE-1/2 and 10 patients with HAE-unknown) were collected. Of the patients with HAE-1/2, 53.4% experienced EM, whereas 43.1% did not. The forearm was the most frequent area of EM (64.5%), followed by the abdomen (29.0%) and upper arm and precordium (19.3%). Of the HAE-1/2 patients with EM, 41.9% always had angioedema following EM, while 29.0% always had colocalization of EM with angioedema. Moreover, 3.2% showed a correlation between the awareness of EM and severity of an angioedema attack. In 60.9% of HAE-1/2 patients with EM, the interval between the awareness of EM and appearance of angioedema was